AU619443B2 - Immunopotentiation - Google Patents

Description

AU-AI-73510/ 87 1 .D INTELLECTUAL PROPERTY ORGANIZATION international Bureau Pv 1

WORI

INTERNATIONAL APPLICATION 6) 1(51) International Patent Classification 4 C07K 15/04, 15/12, C07H 2 1/04 C12N 1/20, 15/00, C12P 19/14 C12P 21/00.21102. A61K 39/385 Up jD fHW T CO ERATION TREATY (PCT) (11) International PublicationNumber: WO 87/106590 Al (43) Internaton~l Publication Date: 5 November 1987 (05.11.87)

I

(21) International Appi$,'ation Number: PCT/AU87/00 107 (22) International Filing XPabte (31) Priority Application Numbers: 16 April 1987 (16.04.87) PH 5559 P1 0846 (32) Priority Dates: (33) Priority Country: 21 April 1986 (2 1.04.86) 13 March 1987 (13.03.87) (74) Agent: SPRUSON FERG T 'SON' Box-3898, Sydney,l NSW 2001-(AL9).

(81) Designated States: AT (E uropean patent), AU, BE (European patent), CH- (Iluropean patent), DE (European patent., DK, Ff, FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent) NL (European patent), NO, SE (European patent), US.

Published ~(2 With international search report. With amended claims.

UL.4 X E 17 D EC 1987 PA 4 NOV 1987 (11) Applicant (for all designated Stat,- except US): BIOEN- TERPRISES PTY. LTD. [AU, 1; 28 Barcoo Street, East Roseville, NSW 2069 (Ab, (72) Inventors; and Inventors/Applicants (for US only) BARNES, Thomas, Michael [AU/AU]; 20 Mooney Street, Lane Cove, NSW 2066 LEHRBACH, Philip, Ralph [AU/ AU], 5 Fiona Avenue, Wahroonga, NSW 2076 (AU).

RUSSELL-JONES, Gregory, John [AU/AU]; 23 Greenfield Avenue, Middle Cove, NSW 2068 (AU), (54)Title: IMMUNOPOTENTIATION cm, dei'etebaml1l lrag.

nsert blunt (rag in icoRV s.te Pt~sm~dCnirut4 (57) Abstract A class of carrier 4iolecules which when linked to an immunogen ckt- enhance the host's immu~e response to tIha' immunogen regardless of whether the complex of carrier and immunogen is )dminlstered parenterally, e~tterally or orally', to the host. The invention also provides processes for rprodudon of compl es according to the invention, as well as i brid DNA sequences encoding comnplexes according to the (invention, reojinbinant DNA molecules bearing said hybrid DNA seque.noes, transformant hosts and vaccines coniprisini ompltxc, of the invention as Well as methods for production of said vaccines.

WO 87/06590 PCT/AU87/00 107 13 TABLE 3 WO 87/06590 PCT/AU87/00107 1

IMMUNOPOTENTIATION

TECHNICAL FIELD The invention relates to a class of molecules which when linked to an immunogen can enhance the host's immune response to that immunogen regardless of whether the complex is administered parenterally, enterallyor orally.

DEPOSITION OF STRAINS Reference to ATCC 67331, is to an E. coli strain deposited with the American Type Culture Collection at 12301 Parklawn Drive, Rockville, MD 20852, USA on 2 March 1987.

BACKGROUND ART In order to protect an animal against an invading pathogen (bacterial, viral or parasite) it is often advisable to vaccinate the animal with the whole organism or with such subunits of the pathogen as to elicit a protective immune response in the host. The Immune response generated to such antigenic challenge can often be augmented by the co-administration of an immunopotentiating agent or adjuvant. The best of these agents are the depot type adjuvants (such as Freund's complete adjuvant, Freund's incomplete adjuvant and montanide). These adjuvants are capable of increasing the antibody response after antigen injection to some to 100 times the level obtained with antigen Injected alone.

Whilst adjuvants such as Freund's complete adjuvant, Freund's incomplete adjuvant and Montanide can greatly enhance the immune response to an antigen, they suffer from some disadvantages. When used with an antigen in an injectable form, large lesions often form at the site of injection, a situation which renders them unsatisfactory for such use In humans, pets or in meat animals. Furthermore, these adjuvants fail to act as Immunopotentiating agents when administered orally or enterally.

DESCRIPTION OF THE INVENTION This invention relates to a class of molecules which when linked chemically or genetically to an immunogen or hapten can enhance the host's Immune response to the Immunogen or hapten regardless of whether the complex is administered parenterally, enterally or orally. In addition their use does not result in the formation of large lesions at injectidn ,Ites.

Molecules which have this activity can be defined as having ,he geeral property of being membrane proteins and the examples described herein ar from specific types of membrane proteins, more specifically thq outer -membrane proteins of Gram negative bacteria, Examples cited WO 87/06590 PCT/AU87/00107 14 rotavirus vaccine.

a~ WO 87/06590 PCT/AU87/00107 specifically Include the TraT protein, an outer membrane protein of certain strains of E. coli which is responsible for the resistance of these strains to killing by serum. Other proteins of this class are the E. coli outer membrane proteins Oi0pA and OmpF. Hhen quantities of TraT, OmpA or OmpF (hereafter called carrier) are injected intramuscularly into mice, without adjuvant, an antibody response is elicited which is comparable to that elicited when a soluble protein such as BSA, flagellin or sheep IgG is mixed with Freund's incomplete adjuvant and then injected. In fact, the antibody response elicited by these outer membrane proteins is so high as to be only marginally increased by adjuvation with Freund's incomplete adjuvant.

It has also been found that oral administration of TraT or OmpA results in the stimulation of significant titres of anti-TraT (1/4096) or anti-OmpA (1/892) serum antibodies.

Similarly it has been found that feeding of moderate quantities (109-10l) of Salmonella or E. coli containing TraT in the outer membrane also enhances production of anti-TraT antibodies.

Covalent coupling of a hapten (Dinitrophenol, DNP), peptide (CSP) or a protein (Bovine Serum Albumin, BSA) to OmpA or TraT also acts to enhance the immune response to the DNP, CSP or BSA.

In a first embodiment the invention provides a complex comprising an immunogen coupled to a carrier molecule, such that the carrier molecule causes th" Immune response of a host to the immunogen to be enhanced when the complex is administered to said host, regardless of whether the complex is administered parenterally,.enterally or orally, wherein said immunogen comprises either an antigen or a hapten and said carrier molecule comprises an integral membrane protein of prokaryote or eukaryote origin.

In a preferred embodiment the carrier molecule is an outer membrane protein of a Gram negative bacterium.

Preferably said Gram negative bacterium is E. coli or a Salmonella species.

More preferably the carrier molecule is the TraT protein or the outer membrane protein 0%pA or OmpF, produced by strains of E. coli.

Preferred immunogens of the invention include CSP, the viral capsid protein VP7 from a rotavirus strain, and all or part of the eukaryotic protein minActivlin.

The tmmnogen-carrier complex may be formed by chemical means Including: conjugation, for instance, by using either a suitable conjugating or linking agent; and modification and/or reaction of I

U~

WO 87/06590 PCT/AU87/00107 3 functional groups present on carrier and/or immunogen.

Thus, the invention provides a process for the production of a complex comprising, an immunogen coupled to a carrier molecule, said carrier molecule being an integral membrane protein (imp), of prokaryote or eukaryote origin and said immunogen comprising either an antigen or a hapten, wherein the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to said host, regardless of whether the complex is administered parenterally, enterally or orally, which process comprises one or more of the following steps: a) reacting the immunogen with the carrier to forn said complex; b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the modified immunogen and carrier to form said complex; c) chemically modifying the carrier to provide at least one functional group capable of forming a chemical linkage and reacting the immunogen and modified carrier to form said complex; d) chemically modifying the immunogen and the carrier t9 provide functional groups capable of forming a chemical linkage, and reacting the modified immunogen and modified carrier to form said complex; e) reacting the immunogen with at least one linking agent and reacting the linked immunogen and the carrier molecule to form said complex; f) reacting the carrier with at least one linking agent and reacting the immunogen and linked carrier to form said complex; g) reacting the immunogen and carrier with at least one linking agent and reacting the linked immunogen and linked carrier to form said complex.

A preferred process of the invention comprises: chemically modifying an immunogen to provide at least one functional group capable of forming a chemical linkage; and (Ii) reacting the modified immunogen and the carrier to form said complex.

The linking agent may contain a disulfide bond or be cleavable by acid, base or periodate. Examples of such linking agents include N-(4-azidophenylthio)phthalimlde, 4,4'-dithiobisphenylazide, dithiobis- (succinimidylpropionate), dimethyl-3,3'-dithiobisproptonimidate.2HC1, 3,3'dithiobis-(sulfosuccinimidylpropionate), ethyl-4-aziodophenyl- 4-dithiobutyrimidateHCl, N-succinimidyl-(4-azidophenyl)-1,3'-dithio- WO 87/06590 PCT/AU87/00107 4 proplonate, sulfosuccinimidyl-2-(m-azido-o-nitrobenzamldo)-ethyl-l,3'dithtoproplonate, sulfosuccinimidyl-2-(p-azldosalicylamido)-ethyl- 1,3'dithiopropionate, N-succinimidyl-3-(2-pyridyldithio)propionate, sulfosuccinlmidyl-(4-azidophenyldithio)-propionate, and 2-iminothiolane.

Preferred cross-linking agents are disuccinimidyl tartrate and bis-E2- (succinlmldyloxycarbonyloxy)-ethyl]sulfone.

Suitably, linking of the carrier and immunogen may be achieved by coupling the carrier to suitable groups of the immunogen.

Where the immunogen-carrier complex is formed by chemical conjugation, for instance, by using either a suitable conjugating or linking agent, preferred conjugating or linking agents include 1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide, glutaraldehyde, m-Maleimido benzoic acid n-hydroxysuccinimide ester, or N, N 1 Dicychohexyl carbodiimide.

The linkage between the immunogen and the carrier molecule may also be made by the preparation of a hybrid protein molecule, such as Is produced by recombinant DNA techniques by the insertion into, or addition to, the DNA sequence coding for the carrier, of DNA coding for the immunogen.

Hence, the invention provides a process for the preparation of said complex of carrier molecule with immunogen, which process comprises preparing a hybrid protein molecule. In a preferred process the hybrid protein molecule is produced by recombinant DNA techniques, by the insertion into, or the addition to, the DNA sequence coding for the carrier, of DNA coding for the immunogen.

The invention also provides a hybrid DNA sequence which consists of: a first DNA sequence comprising a DNA sequence which acts as a coding sequence for at least part of an integral membrane protein of prokaryote or eukaryote origin fused to a DNA sequence coding for the amino acid sequence of an immunogen; or a second DNA sequence which hybridizes to said first DNA sequence, from whatever source obtained, including natural, synthetic and semi-synthetic sources; a DNA sequence related by mutation, including single or multiple base substitutions, deletions, insertions and inversions to said first DNA sequence; or a DNA sequence comprising sequences of codons which, on expression, code for a polypeptide displaying similar Immunological or biological activity to a polypeptide coded for on expression of the codons of any of the foregoing hybrid DNA sequences and inserts.

Preferred hybrid DNA sequences of the invention code for at least THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A complex comprising an immunocen coupled to a 1, part of TraT, OmpF or OmpA, linked to a DNA sequence coding for the amino acid sequence of an immunogen such that the resulting TraT-(OmpF or OmpA) hybrid proteins are exported to and exposed on the host cell surface.

The invention also provides a fused gene comprising a hybrid DNA sequence of the invention fused to a portable promoter. A preferred promoter according to the invention, is the PL promoter of the bacteriophage lambda.

Further, the invention provides, a recombinant DNA molecule which comprises a hybrid DNA sequence according to the invention and vector DNA, wherein the vector DNA is plasmid, bacteriophage, viral or cosmid DNA.

A preferred recombinant DNA molecule of the invention includes an expression control sequence operatively linked to the hybrid DNA sequence.

Particularly preferred recombinant DNA molecules according to the invention include: pBTA371, pBTA439, S pBTA449, pBTA450 and pBTA586.

O*o• Within the scope of the invention is a process for the manufacture of a recombinant DNA molecule which process comprises: introducing into a cloning vehicle, a hybrid DNA sequence according to the invention.

Preferably the process also includes the step of introducing an expression control sequence into the cloning vehicle.

The invention also provides a host transformed with at least one recombinant DNA molecule according to the invention.

o. Suitable hosts include E. coli and Salmonella sp.

A preferred transformant is ATCC 67331 (also designated CCTCC 87026). ATCC 67331 is an E. coli K12 C600 lambda lysogen containing plasmid pBTA439. It has an inhouse designation of BTA 1349.

Also included within the scope of the invention is a process for transforming a host, which process comprises the step of: introducing into a host a recombinant DNA molecule 1,IO1AA/CB 1 17 7. A complex according to claim 6 wherein the coupling is by chemical coniuaation comnri in nao nf th 0 be 06:.

p.i

I

5A according to the invention.

In a further embodiment the invention provides the complex of carrier with immunogen adapted for parenteral injection into a host or adapted for oral or enteral administration, to elicit both a humoral and mucosal antibody response.

Included within the scope of the invention is a process for the preparation of the complex of carrier with immunogen in a form adapted for parenteral, enteral or oral administration to a host which process comprises preparing the complex and adding it to a pharmaceutically acceptable diluent.

Preferably the invention provides a whole bacterial cell vaccine comprising a hybrid protein according to the invention is exposed on the bacterial cell surface for presentation to the immune system. The (1r *0

S

101AA/CB b) chemically modifying the immunogen to provide I 1 I- niCL I i i *Ptn 4 iP ^t i A-i^<1>A n I WO 87/06590 PCT/AU87/00107 6whole cell vaccine may be a live or killed whole cell oral vaccine.

Alternatively the hybrid protein can be purified from the cell membrane or cellular contents and used as a subumit vaccine administered parenterally, enterally or orally.

The Invention also provides a orocess for the manufacture of a microorganism with the genetic information for the biosynthesis of a hybrid protein comprising at least an immunogen and a carrier comprising at least part of an imp of prokaryote or eukaryote origin, such that the resulting hybrid peptide is exposed on the host cell surface which process comprises culturing a microorganism carrying the necessary genetic information.

Where the microorganism Is used to provide a subunit vaccine, the process additionally comprises purifying the hybrid peptide from the cell membrane or cellular contents.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 Modifications of the immune response by adjuvants.

Rabbits were injected i.m. with TraT, (Fig.la) and BSA (Fig.lb) alone or in combination with various adjuvants. TraT and BSA were mixed with F.I.A. Montanide 888 Alhydrogel saline Figs. la lb. A comparison of the antibody response generated to TraT OmpA (N I) and OmpF injected in saline is presented in Fig. Ic.

Figure 2 Stimulation of the antibody response to DNP and BSA by coupling to TraT and OmpA.

Dinitrophenylated preparations of TraT Omp A (X X) and BSA were compared for their ability to stimulate anti-carrier (Fig. 2a) and anti-DNP antibody responses (Fig. 2b) following im injection. The antibody response to TraT 0) and Omp A injected alone was also determined, Similarly BSA was injected in saline mixed in FIA T) or covalently conjugated to TraT or Omp A and the anti-BSA response was determined (Fig. 2c). The anti-TraT and antl-Omp A responses to these congugates are shown In Fig. 2a. The immunopotentiating activity of Imps was examined when BSA was Injected covalently linked to TraT V) or Omp A when It was mixed with TraT A) or Omp A or when it was injected at a separate site from TraT A) or Omp A (Fig, 2d).

16. A complex according to claim S5 wherein the complex COMtt risea ann Pri fift*nn Ytrtni il~LICI WO 8'7/06590; PCT/AU87/00107 7 Figure 3a shows the construction of the plasmids and pBTA449, pBTA439 and pBTA371 Figure 3b shows an SDS-PAGE and Western for expression of TraT and the TraT-VP7 fusion protein.

Figure 3c shows an autoradiograph of cell surface labelled E.coli expressing TraT (Lane TraT-VP7 (Lane 3) and control (Lane 125 Cells were labelled with 125 and lacioperoxidase.

Figure 4a shows the construction of the plasmids pBTA450 and pBTA586.

Figure 4b shows the SDS polyacrylamide gel of a TraT minactivin hybrid protein (TraTMIN) expressed from pBTA586 Abbreviations (Fig. 3 and Resistance to; ampicillin, Apr; chloramphenico!, Cmr; mercuric chloride, Hg tetracycline, Tc; VP7 structural gene, VP7; TraT structural gene, TraT,; TraT VP7 gene fusion, TraT-VP7; lambd bacteriophage PL promoter region, PL.Restrlction endonucleases, Al, Alul; A, AvaI; D, Dral B, BamHI; E, EcoRI; N, NdeI; Pv, PvuII; RV, EcoRV; Ss Sspl.

BEST MODE OF CARRYING OUT THE INVENTION The following examples illustrate preferred embodiments of the present invention, and are in no way limiting on the scope of the invention.

EXAMPLE 1 Isolation of TraT, OmpA and OmpF E.coll (Strain BTA 1352 containing the plasmid pBTA439) were grown in a fermenter at 30 0 C in MEB medium. Cells were harvested following 2 hours of heat induction of TraT at 42

C

C. Bacteria were concentrated to 2 litres using a 0. I hollow fibre cartridge in a Amicon DCIOLA concentrator. The cells were then washed with 10 litres of distilled water and reconcentrated to 800ml. The bacterial slurry was then removed from the concentrate and the outer membrane proteins (TraT, OmpA and OmpF) extracted from the cells by the addition of 200m of 1M sodium acetate buffer pH 2.5, followed by 1 litre of 10% cetrlmide (Sigma) in 40% ETOH plus IM Ca Cl 2 The extraction was allowed to proceed overnight at room temperature, (RT) after which the bacteria were removed by centrifugation (17,000 xg, 20 min).

TraT and OmpF were precipitated from the supernatant by the addition of ethanol to 50% and centrifugation (40000 xg, 10 min). OmpA was then precipitated from the final supernatant by addition of ethanol to Ion Exchange Chromathraphy The 50% ethano iellet containing OmpF and TraT was resuspended In Na acetate bufer pH5.0 contaning 0.5% Zwlttergeit, and loaded onto a S 5x50cm column of DEA' Sepharose (Pharmacia Fine Chemicals) previously I o o o A c 28. A process for the production of a recombinant DNA mir-.arlematlAr,!Nr feN ani tt i nl rlaa 'd t-r '1c Ass4e^l WO87/06590 PCT/AU87/00107 -8equilibrated with 20mM Na Acetate buffer pH5.0 containing 0.1% Zwittergent. TraT was found in the column flow through, and bound OmpF was eluted from the column using a linear gradient of O-1.OM NaCl in equilibration buffer. Fractions were analysed by SDS-PAGE using a modification of the method of Laemmli (Laemmli, U.K. NATURE (LOND) 227:680 1970; Salit et al., J.Exp. Med. 151:716. 1980) and fractions containing isolated TraT or OmpF were pooled and concentrated by ethanol precipitation.

Sephacyyl S-300 chromatography Tke 80% ethanol pellet containi;ig OmpA was resuspended in 1% SOS in mM Tris. HC1.pH 8.8. Fractions were collected, analysed by SDS-PAGE and fractions containing OmpA were pooled and concentrated by ethanol precipitation.

Proteins purified by the above methods were found to be free of LPS when examined by SDS-PAGE and silver stained by the method of Tsai C.M. and Frasch, C.E. Anal. Biochem 119:115. (1982).

Dinitrophenylation of Carriers TraT, OmpA and OmpF were dintrophenylated according to the method of Little and Eisen "Methods in Immunology and Immunochemistry" (E.D.

Williams, CA and Chase, 1, p.128 Academic Press, N.Y. (1967).

Briefly, carriers (in 0.1M carb/bicarb buffer pH9.5) were reacted with a 0.1M solution of DNFB (in Acetone) overnight at RT. The proteins were then dialysed extensively against the coupling buffer.

Glutaraldehyde coupling Bovine serum albumin (BSA) (from Sigma Chemical Co. St. Louis, Miss.) was coupled to TraT, OmpA and OmpF using the two step glutaraldehyde procedure of Avrameus et al (1978). Briefly, BSA was reacted with 0.2% glutaraldehyde for 2 hrs at R.T. The protein was then dialysed overnight against carb/bicarb buffer pH 9.5 followed by the addition of omp's at a molar ratio's of 1:1 BSA:omp and reacted for 24 hrs at RT. Finally ethanolamine (Sigma) was added to a final concentration of 0.1M, (1 hr, RT) followed by overnight dialysis at 4C against 0.1M carb/bicarb buffer pH ANTIGEN ADMINISTRATION 1. Rabbits New Zealand white rabbits (2-2.5kg) were injected ,itramuscularly with antigen In 0.5ml of sterlte physiological saline.

Injections were performed on days 0 and 36. Weekly bleedings were obtained from the longitudinal vein in the rabbits ear and antibody titres were measured by a standard ELISA using TraT, OmpA, BSA or DNP-sheep IgG as coating antigens.

t parental# oral, or enteral administration to a host which WO 87/06590 PCT/AU87/00107 9 2. Mice Female C57BL/6J mice (18-22gm) were obtained from the Animal Resources Centre (Perth, Western Australia). All mice were starved for 3-4 hours prior to oral or intramuscular administration of antigens.

Mice were fed antigen at appropriate concentrations in 0.5ml of 0.1M carb/blcarbonate buffer pH9.5 using a specially prepared feeding needle.

Parallel doses of antigen were injected in 0.1ml of sterile physiological saline, into the left hind leg. Groups of 5 mice receiving antigen either orally or im were given two identical doses of antigen, on day 0 and day 14. A blood sample was taken (approx. 0.5ml) from the retro-orbital plexus on day 14 and day 21. Mice were then sacrificed by cervical dislocation and gut washes performed on the small intestine in the following manner. The small intestine was carefully removed and a small quantity of washing buffer (1.0ml, 30 mM Tris.HCl pH8.8, 0.9% NaCl, 50 nM EDTA plus 1.0% Tween 20) introduced into the lumen of the gut via a blunt ended feeding needle. After gently kneading the intestine and contents were squeezed out through forefinger and thumb. Gut washes so obtained were immediately centrifuged to remove debris and stored at -20 0 C until assayed. Blood samples were allowed to clot at 4 0 C before remov&l of thp serum and storage at -20 0

C.

Enzyme Linked Immunosorbent Assay (ELISA) The ELISA for the determination of antibody titres was perfomed as described previously by Russell-Jones et al. J. Exp. Med 160:1467,(1984).

Titres are expressed as the reciprocal of the antiserum dilution, which gave a ELISA reading of 0.5 after 45 mins at 37 0

C.

EXAMPLE 2 Effect of adjuvant on the antibody response to integral membrane proteins The potential of imps to act as self adjuvanting molecules when injected i.m. was examined. The antibody titre generated when TraT Fig (la, x x) or BSA Fig (tb x x) were injected alone was compared to that generated when TraT (Fig a) or BSA (Fig Ib) were mixed with a number of adjuvants.

Intramuscular administration of TraT, in saline quickly elicited high Iitres of serum antibody to the immunizing agent (Fig la). In fact the titres generated by TraT in saline could only be increased by a factor of 4-8 fold by injection of this antigen In adjuvants such as montanide or FIA (Fig. la). This is in direct contrast to the response generated by the soluble antigen BSA. In this case a poor antibody response was generated to the antigens administered in saline, but was markedly WO 87/06590 PCT/AU87/00107 10 increased 60-100 fold by injection of the antigen in FIA or montanide (Fig. Ib).

Similarly injection of OmpA and OmpF In saline alone also elicited high serum Ab titres. In fact, surprisingly similar antibody titres were elicited by injection of 100g TraT, OmpA or OmpF (Fig 1c).

EXAMPLE 3 Examination of the adjuvanting ability of Immunogen imp complexes TraT and OmpA were examined for their ability to augment anti-hapten (DNP) and anti-protein (BSA) responses. The two Imps were substituted with DNP using dinitrofluorobenzene (see Example 1) or were glutaraldehyde cross-linked to BSA (see Example 1) and then injected 1.m, Coupling of DNP or BSA to either TraT or OmpA had little effect on the generation of an anti-imp response (Fig. 2a, cf Ic).

Dinitrophenylation of the imps did however increase the anti-DNP response some four to sixteen fold higher than the response seen to DNP-BSA when it was injected In saline (Fig, 2b). Similarly the anti-BSA response was greatly enhanced when BSA was administered in FIA (fig. 2c). The immunopotentiating effect of TraT or OmpA on the anti-BSA response was greatest when BSA was covalently linked to the imps, In fact Injection of BSA at a separate site from the imp actually depressed the secondary response to BSA (cf 2d and 2c).

EXAMPLE 4 Effect of Dose on the immune response to TraT The effect of Increasing dose of TraT administered either 1,m, or per os. was examined in mice, Groups of 5 mice were immunized by Intramuscular injection or oral feeding with increasing doses of TraT. Mice received doses on day 0 and day 14, On day 21 mice were bled, sacrificed and gut washes obtained.

Antibody titres were increased by ELISA As can be seen from Table I increasing doses of TraT adminlsted orally or parenterally led to a dose dependent increase in ser, hnti-TrT Ab response.

Parenteral administration was however much more effective than Oral administratlon.

WO 87/06590 ORIGINAL PT/AU87/001(7 11 SHEETS, SHEET 1 WO 87/06590 rA7017 PCF/AU87/00107 11 TABLE V Dose of anti gen 0,1 2 100 200 400 Route"cf administration intramuscular per os serum serum 2,048 3,565 10,809 5,405 28,526 24,833 49,667 65,536 150,562 86,475 IgG 900 1 ,300 1 ,900 400 7,280 6,040 13,020 16,000 64,000 1 9,000 7 2 13.9 12.0 9.1 97 64 675 97 I gG 2.6 2 9 2 3 25 36 400 45 Gut 7 6 56 42 18 7 11 (14 24 EXAMPLE Examination of the hapten density on the ability of the imps to act as, car,.,Iers for anti-ONresponse TraT, OmpA and. 0mpF were substituted with different ratios of DNP-,imp as describe~d in kampl1tx 1. Groups of 5 mice were injected i m with S0pg doses of the DNP :carrier complex on days 0 and 14. On day 21 mice were bled and the Ab titres determined by ELISA.

Increasing the substitution ratio of UT4 to carrier from 0.5 1 to 4 I increased the anti-hapten response considerably. Substitutions of greater than 10 I appeared to decrease the anti-hapten response.

WO 87/06590

ORIGINAL

11 SHEETSo SHEET 2 PCIT/AU87/00107 -1-i:_il WO 87/06590 PCT/AU87/00107 12 TABLE 2 Antigen DNP TraT DNP-ompA DNP omp F Substitution 0.5 1 1:1 2 1 4 :1 0.5 1 2 4 0.5 1 2 4 Route i.m 1.m i.m i.m i.m 1.m i.m 1.m i.m Antibody response (serum IgG) 21 13 337 71 1552 536 3104 954 EXAMPLE 6 anti-CSP resoonse bv couolinq to TraT Generation of an A synthetic peptide derived from the circumsporozoite protein (CSP) antigen of P. falciparum of the following sequence: NH 2 Cys (Asn Pro Asn Ala) 4 was synthesized and used to conjugate to TraT in order to examine the adjuvating effect of TraT for the peptide antigen.

The CSP antigen was coupled to Tra T using either glutaraldehyde or maleimidobenzoic acid n-hydroxy succlnimide ester (MBS). Conjugates prepared In this way were injected into a) rabbits on day 0, day 28, which were then bled on day 38, or b) groups of 5 mice on day 0 and 14. Mice were then bled on day 21'. Antibody titres were determined as described previously.

Immunization of rabbits or mice with the CSP antigen coupled to TraT using either glutaraldehyde or MBS, resulted in the stimulation of an anti-CSP response which was comparable to that seen when the antigen was coupled to BSA and injected in montanide.

4 WO 87/06590 ORrINAL 11 SHEETS, SHEET 3 PCT/AU87/00107 *LIL-C17C-n*LI I WO 87/06590 PCT/AU87/00107 13 TABLE 3 Antigen Coupling Animal Dose Antibody Response (serum) procedure (Fg) anti TraT anti CSP CSP-TraT glutaraldehyde rabbit 200 28,526 147 CSP-TraT MBS rabbit 200 12,417 1,024 CSP montanide rabbit 200 28 CSP-BSA+montanide glutaraldehyde rabbit 200 2,353 CSP-TraT glutavaldehyde mouse 50 228,209 32 CSP TraT MBS mouse 50 3,566 128 CSP montanide mouse 50 CSP-BSA montanide glutaraldehyde mouse 50 9 EXAMPLE 7 Gnetic construction of a TraT-immunogen protein complex.

The gene coding for the TraT protein is located on the R plasmid R100 ,r R6-5) and the nucleotide sequence of this gene has been determined (1)gata et al, J. Bacterlol 151: 819-827). TraT is an oligomeric lipoprotein situated in the outer membrane which is simultaneously exposed at the cell surface and associated with peptidoglycan, an internal structure. Using these facts a plasmid vector was constructed (Fig, 3a) by initially cloning a 6.0 kb EcoRI fragment of the R100 plasmid which contains TraT into the multicopy plasmid pBR329. FL deletion of an unwanted 3 kb BamHI fragment and inactivation, by insertion of a small blunted ended HaeIII fragment of M13mp8, in an EcoRV site produced pBTA449. This vector plasmid contains the natural TraT promoter which directs the synthesis of TraT. The expression of TraT (or TraT-hybrid proteins subsequently constructed) can be boosted by the replacement of the weak TraT natural promoter with the strong lambda bacteriophage PL promoter In plasmid pBTA439 Fig. 3a or pBTA586 Fig. 4a). The TraT gene contains an EcoRV site (Unique to pBTA449) where foreign DNA sequences may be Inserted such that fusions between TraT and the encoded foreign protein are exported correctly to the cell surface and result in exposure of the foreign protein segment at the cell surface.

In one example the gene for a viral capsid protein (VP7) was used to form TraT-VP7 hybrid proteins. VP7 is a structural protein of rotavirus and antlbodie" raised against purified VP7 protein effectively neutralize viral Infecti4lty in cell culture (Dyall-Smlth etal 1985 In Infectious Diarrhoea in they.oung ed. S.Tzipori). Thus the VP7 protein, in appropriately expressedso(or, s a prime candidate for Inclusion in a WO 87/06590 PCT/AU87/00107

ORIGZNAL

IX SHEETS, SHEET 4.

WO 87/590 PCT/AU87/00107 14 rotavirus vaccine.

An Alul PvuII restriction fragment of the rotavirus NCDV VP7 gene was cloned into the EcoRV site of plasmid pBTA449 and subsequently overexpressed with the PL promoter (pBTA371, Fig. 3a). For expression the plasmtd pBTA371 was used to transform E.coli K-12 strain N4830 (Joyce etal, PNAS 80, 1830-1834 1983) which contains the thermolabile cI repressor of Lambda. Cells transformed with pBTA371 were grown overnight in MEB medium (Mott et al PNAS 82, 88-92 1985) with 1OOug/ml ampicillin at 300C.

Cells were diluted in MEB medium, grown at 30 0 C to an OD 600 of 1.0 when prewarmed MEB medium was added in equal volume to equilibrate the temperature to 42*C. Following 4 hours of growth at 42 0 C the cells were harvested and examined for induction of the TraT-VP7 hybrid protein. In E.coli N4830 high level expression of the TraT-VP7 protein complex (10-15% total cell protein or greater than 500,000 copies per cell) was observed.

A significant proportion of this complex was present in the outer membrane fraction (Fig. 3b, 3c).

In another example a method of producing a protein that is a hybrid of part of the TraT protein coding sequence and all or part of a eukaryotic protein coding sequence, minactivin, follows.

As shown in Fig. 4a the plasmid pBTA440 was digested with SspI and Dral and a IIIObp fragment wa, isolated from an agarose gel. This fragment was ligated to the vector pBTA449 digested with EcoRV creating pBTA450.

pBTA450 was then digested with Aval and a purified 2800 bp fragment ligated to the plasmid pLK57 digested with AvaI to create plasmid pBTA586.

This places part of the minactivin coding sequence under the control of the lambda PL promoter and fused to, the coding sequence of the first 80 amino acids of TraT gene, the first 20 of which constitutes a signal sequence that results in the hybrid appearing in the outer membrane of E.coli. This signal sequence is cleaved off during transport to the outer membrane, which is the normal location of the TraT protein.

When plasmid pBTA586 is transformed into an appropriate host, such as N4830, and Induced with temperature shift as described above, the TraT-mlnactivin hybrid protein appears in the outer membrance fraction, as shori In Figure 4b.

EXAMPLE 8 Oral eeding of strains expressing TraT in th outer membrane Pemale C57B1/65 mice (20-25 g) were -ed 10-10 bacteria (E.

col!i a ga1 tE utant of S. typhimurlum) expresing TraT In their outer membranes. Controls received the same strains without the TraT protein.

WO 87/06590 ORIGINAL PCT/AU87/00107 1.1 SHEETS, SHEET ;L i I 'IC-L i WO 87/016590 PCT/AU87/00107 15 After 1 week mice were bled and the anti-TraT titres mtasured as outlined previously.

Results are expressed in Table 4 as reciprocal antibody titre and represent the average of 10 mice.

TABLE 4 Antibody Resoonse to Orally Administered Nhole Bacteria Strain E. coli TraT Salmonella

I

Anti TraT Serum Intestine 3 5.2 350 15 12 2 650 6 :NDUSTRIAL APPLICATION Anti OmpA Serum Intestine 14 2 110 2 ND ND ND ND The current invention is of use in the preparation of vaccines for use in humans, pets and meat animals, and in general for potentiating the response to in antigen on oral, enteral or parenteral administration.

WO 87059 RIIA I WO 87/06590 PCT/AU87/00107

ORIGINAL

11 SHEETS, SHEET 6

Claims (36)

1. A complex comprising an immunogen coupled to a carrier molecule, characterised in that the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to the host, regardless of whether the complex is administered parenterally, enterally or orally, and the enhancement is not substantially increased by the addition of an adjuvant to the complex when the complex is administered to the host, wherein the immunogen comprises either an antigen or a hapten and the carrier molecule comprises all or part of the TraT protein, the outer membrane protein OmpA, or the outer membrane protein OmpF, produced by strains of E. coli.

2. A complex comprising an immunogen coupled to a 15 carrier molecule, characterised in that the carrier molecule causes the immune response of a host to the immunogen to be enhanced when the complex is administered to the host, 0*. regardless of whether the complex is administered parenterally, enterally or orally, and the enhancement is not 20 substantially increased by the addition of an adjuvant to the complex when the complex is administered to the host, wherein the immunogen comprises either an antigen or a hapten and the carrier molecule comprises all or part of the TraT protein, the outer membrane protein OmpA, or the outer membrane 25 protein OmpF, produced by strains of Salmonella.

3. A complex according to claim 1 or claim 2 wherein the carrier molecule is the protein TraT.

4. A complex according to any one of claims i to 3 wherein the immunogen is CSP, the viral capsid protein VP7 from a rotavirus, or all or part of minactivin. A complex according to claim 4 wherein the immunogen is CSP.

6. A complex according to any one of claims 1 to wherein coupling of the carrier to the immunogen is by chemical means. r i WO 87/06590 ORIGINAL SSHEETS, SHEET 8RIGINAL 11 SHEETS, SHEET 8 PCT/AU87/00107 17

7. A complex according to claim 6 wherein the coupling is by chemical conjugation comprising use of either a conjugating or linking agent.

8. A complex according to claim 7 wherein the conjugating or linking agent is l-ethyl-3-(3-dimethyl- aminopropyl)carbodiimide, glutaraldehyde, m-maleimido benzoic acid n-hydroxysuccinimide ester, or N, N 1 dicyclohexyl carbodiimide.

9. A complex according to claim 7 wherein the linking agent contains a disulfide bond or is cleavable by acid, base or periodate. A complex according to claim 9, wherein the linking agent is selected from N- (4-azidophenylthio)phthalimide, 4, 41 -dithiobisphenylazide, dithiobis- (succinimidyipropionate) is dimethyl-3,3'dithiobispropionimidate.2HC1, 3,3'-dithiobis- (sulfosuccinimidylpropionate) ethyl-4- aziodophenyl-1, 4-dithiobutyrimidate.HC1, N-succinimidyl- (4-azidophenyl) 1,3' -dithiopropionate, sulfosuccinimidyl-2-(m-azido-o- nitrobenzamido)- ethyl-1,3'-dithiopropionate, sulfosuccinimidyl-2- (p-azidosalicylamido) -ethyl- 1,3 'dithiopropionate, N-succinimidyl-3- (2- pyridyldithio)propionate, sulfosuccinimidyl-(4- azidophenyldithio)-propionate, 2-iminothiolanedisuccinimidyl tartrate and bis- (succinimidyloxycarbonyloxy) -ethyl] 25 sulfone.

11. A complex according to claim 10 wherein the linking agent is 2-'iminothiolanedisuccinimidyl tartrate or bis- [2- (succinimidyloxycarbonyloxy) -ethyl] sulf one.

12. A process for the preparation of a complex according to any one of claims 1 to 11 which process comprises coupling the carrier molecule to the immunogen by chemical means.

13. A process according to claim 12 wherein the process comprises one or more of the following steps: a) reacting the immunogen with the carrier to form the complex; 6OAAJ/43/26.09.91 WO 87/06590 PCT/AU87/00107 ORIGINAL 11 SHEETS, SHEET 9 15 25 V 20 b) chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage, and reacting the modified immunogen and the carrier to form the complex; c) chemically modifying the carrier to provide at least one functional group capable of forming a chemical linkage and reacting the immunogen and the modified carrier to form the complex; d) chemically modifying the immunogen and the carrier to provide functional groups capable of forming a chemical linkage, and reacting the modified immunogen and the modified carrier to form the complex; e) reacting the immunogen with at least one linking agent and reacting the linked immunogen and the carrier molecule to form the complex; f) reacting the carrier with at least one linking agent and reacting the immunogen and the linked carrier to form the complex; g) reacting the immunogen and the carrier with at least one linking agent and reacting the linked immunogen and the linked carrier to form the complex.

14. A process according to claim 13 which process comprises: chemically modifying the immunogen to provide at least one functional group capable of forming a chemical linkage; and (ii) reacting the modified immunogen and the carrie to form the complex. A complex according to any one of claims 1 to wherein the coupling is produced by recombinant DNA techniques. .li~il i? l; r~~ WO 87/06590 PCT/AU87/00107 ORIGINAL 11 SHEETS, SHEET t i. /9

16. A complex according to claim 15 wherein the complex comprises a fusion protein molecule.

17. A process for the preparation of a complex according to claim 16, which process comprises preparing a fusion protein molecule by recombinant DNA techniques.

18. A process according to claim 17 wherein the complex is produced by inserting into or adding to the DNA molecule coding for the carrier, DNA coding for the immunogen.

19. A hybrid DNA molecule comprising a DNA molecule which encodes a complex according to any one of claims 1 to 4. A hybrid DNA molecule according to claim 19 wherein the hybrid DNA molecule codes for at least part of TraT linked to a DNA molecule coding for the amino acid sequence of an immunogen.

21. A hybrid DNA molecule according to claim 19 or the DNA molecule coding for a TraT, OmpF or OmpA fusion protein capable of being exported to and exposed on the surface of a host cell.

22. A fused gene comprising a hybrid DNA molecule according to any one of claims 19 to 21 fused to a portable promoter.

23. A fused gene according to claim 22 wherein the promoter is the PL promoter of the bacteriophage X. .25 24. A recombinant DNA molecule comprising a hybrid DNA molecule or fused gene according to any"one of claims 19 to 23 and vector DNA. A recombinant DNA molecule according to claim 24 wherein the vector DNA is of plasmid, bacteriophage, viral or cosmid origin.

26. A recombinant DNA molecule according to claim which comprises an expression control sequence operatively linked to the hybrid DNA molecule.

27. The recombinant DNA molecule pBTA371, pBTA450 or pBTA586 as hereinbefore defined. 1101AA.1/435/26.09.91 I/ I WO 87/06590 ORIGINAL PCT/AU87/00107 11 SHEETS, SHEET 11

28. A process for the production of a recombinant DNA molecule according to any one of claims 24 to 27 which process comprises introducing into vector DNA, a hybrid DNA molecule or fused gene according to any one of claims 19 to 23.

29. A process according to claim 28 which process additionally comprises introducing an expression control sequence into the vector DNA. A transformant host comprising a host cell transformed with at least one recombinant DNA molecule according to any one of claims 24 to 27.

31. A transformant host according to claim 30 wherein the host is E. coli or a Salmonella species.

32. A process for the transformation of a host comprising: introducing into a host a recombinant DNA molecule according to any one of claims 24 to 27.

33. .A whole bacterial cell vaccine comprising a fusion protein according to claim 16 exposed on the bacterial cell surface for presentation to the immune system. 20 34. A whole cell vaccine according to claim 33 which vaccine is a live or killed whole cell oral vaccine.

35. A vaccine comprising a fusion protein according to claim 16 purified from the cell membrane or cellular contents. 25 36. A process for the manufacture of a microorganism with the genetic information for the biosynthesis of a fusion protein according to claim 16 such that the resulting fusion protein is exposed on the host cell surface, which process comprises culturing a microorganism carrying the necessary genetic information.

37. A process for the production of a subunit vaccine which process comprises purifying a fusion protein according to claim 16 from the cell membrane or cellular contents of a microorganism produced by a process according to claim 36.

38. A process for the preparation of a complex according to any one of claims i to 11 in a form adapted for 21101AA. 1/435/26.09.91 i r t parental, oral, or enteral administration to a host which process comprises: preparing the complex and adding it to a pharmaceutically acceptable diluent.

39. A complex according to any one of claims 1 to 11 adapted for parenteral, enteral and oral administration to a host. A complex substantially as hereinbefore described with reference to any one of Examples 3, 5, 6, or 7, excluding DNP-BSA complexes and CSP-BSA complexes.

41. A process for the preparation of a complex substantially as hereinbefore described with reference to any one of Examples 1, 3, 5, 6 or 7, excluding DNP-BSA complexes and CSP-BSA complexes.

42. A hybrid DNA molecule substantially as hereinbefore described with reference to Example 7, excluding the plasmids pRB 329, pBTA 439, pBTA 440, pLK 57 and R100.

43. A fused gene substantially as hereinbefore defined with reference to Example 7.

44. A recombinant DNA molecule substantially as hereinbefore described with reference to Example 7, excluding the plasmids pBR 329, pBTA 439, pBTA 449, pBTA 440, pLK 57 and R100. A transformant host substantially as hereinbefore described with reference to Example 7.

46. A process for the transformation of a host, substantially as hereinbefore described with reference to Example 7.

47. A process for the manufacture of a microorganism with the genetic information for the biosynthesis of a hybrid protein substantially as hereinbefore described with reference to Example 7. Dated this 28th day of October 1991 BIOENTERPRISES PTY LTD By their Patent Attorneys I N GRIFFITH HACK CO 44 A INTERNATIONAL SEARCH REPORT l .Inltntlonr l ApolicatiOn No PCT/AU 87100107